Publications by authors named "Steven Bair"

Claim this Profile
G
Ganciclovir-resistant CMV encephalitis in a mantle cell lymphoma patient on pirtobrutinib: Case report.
Rebecca Unterborn, Karrine Brade, Steven M Bair, Chia-Yu Chiu

IDCases· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Navigating the landscape of personalized oncology: overcoming challenges and expanding horizons with computational modeling.
Melike Sirlanci, David Albers, Jennifer Kwak, Clayton Smith, Tellen D Bennett, Steven M Bair

J Am Med Inform Assoc· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Loncastuximab in high-risk and heavily pretreated relapsed/refractory diffuse large B-cell lymphoma: a realworld analysis from 21 US centers.
Viktoriya Zelikson, Ashwath Gurumurthi, Yazeed Sawalha, Kaitlin Annunzio, Aditi Saha, John Baird, Steven Bair, Katelin Baird

Haematologica· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
DA-R-EPOCH May Mitigate the Adverse Prognostic Implication of the Diagnosis-to-Treatment Interval (DTI) in Large B-Cell Lymphomas.
Jessica Allen, Diana Abbott, Joy Eskandar, Steven M Bair, Bradley Haverkos

Clin Lymphoma Myeloma Leuk· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Molecular Disease Monitoring in Patients With Relapsed/refractory B-Cell Lymphoma Receiving Anti-CD19 CAR T-Cell Therapy.
Meryl Colton, Enkhtsetseg Purev, Bradley Haverkos, Steven Bair, Jagar Jasem

Clin Lymphoma Myeloma Leuk· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Frontline chemoimmunotherapy with nivolumab and dose-adjusted EPOCH in peripheral T-cell lymphoma: a phase 1 trial.
Bradley Haverkos, Jasmine Zain, Manali Kamdar, Alexander Neuwelt, Eduardo Davila, Steven Bair

Blood Adv· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of cumulative dose of brentuximab vedotin on outcomes of frontline therapy for advanced-stage Hodgkin lymphoma.
Raphael E Steiner, Steven R Hwang, Arushi Khurana, Thomas M Habermann, Narendranath Epperla, Katelin Baird, Steven M Bair

Blood Adv· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Brentuximab vedotin plus AVD for Hodgkin lymphoma: incidence and management of peripheral neuropathy in a multisite cohort.
Jackson T Bowers, Jacob Anna, Steven M Bair, Kaitlin Annunzio, Narendranath Epperla

Blood Adv· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A validated composite comorbidity index predicts outcomes of CAR T-cell therapy in patients with diffuse large B-cell lymphoma.
Geoffrey Shouse, Andy Kaempf, Max J Gordon, Andy Artz, David Yashar, Steven M Bair

Blood Adv· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Brentuximab vedotin in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone as frontline treatment for patients with CD30-positive B-cell lymphomas.
Jakub Svoboda, Steven M Bair, Daniel J Landsburg, Sunita Dwivedy Nasta, Sarah J Nagle

Haematologica· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Checkpoint blockade treatment sensitises relapsed/refractory non-Hodgkin lymphoma to subsequent therapy.
Nicole A Carreau, Philippe Armand, Reid W Merryman, Ranjana H Advani, Michael A Spinner, Steven M Bair

Br J Haematol· October 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Checkpoint Blockade Treatment May Sensitize Hodgkin Lymphoma to Subsequent Therapy.
Nicole A Carreau, Orrin Pail, Philippe Armand, Reid Merryman, Ranjana H Advani, Steven Bair

Oncologist· October 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of Treatment Beyond Progression with Immune Checkpoint Blockade in Hodgkin Lymphoma.
Reid W Merryman, Nicole A Carreau, Ranjana H Advani, Michael A Spinner, Alex F Herrera, Steven M Bair

Oncologist· June 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Hematopoietic stem cell transplantation for blood cancers in the era of precision medicine and immunotherapy.
Steven M Bair, Joshua D Brandstadter, Emily C Ayers, Edward A Stadtmauer

Cancer· January 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Outcomes and Toxicities of Programmed Death-1 (PD-1) Inhibitors in Hodgkin Lymphoma Patients in the United States: A Real-World, Multicenter Retrospective Analysis.
Steven M Bair, Lauren E Strelec, Tatyana A Feldman, Gulrayz Ahmed, Philippe Armand

Oncologist· July 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Response-Adapted Treatment Strategies in Hodgkin Lymphoma Using PET Imaging.
Steven M Bair, Jakub Svoboda

PET Clin· July 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Accelerating chimeric antigen receptor therapy in chronic lymphocytic leukemia: The development and challenges of chimeric antigen receptor T-cell therapy for chronic lymphocytic leukemia.
Steven M Bair, David L Porter

Am J Hematol· May 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immunotherapy for the Treatment of Hodgkin Lymphoma: An Evolving Paradigm.
Steven M Bair, Anthony Mato, Jakub Svoboda

Clin Lymphoma Myeloma Leuk· June 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Outcomes of patients with relapsed/refractory Hodgkin lymphoma progressing after autologous stem cell transplant in the current era of novel therapeutics: A retrospective analysis.
Steven M Bair, Lauren Strelec, Sarah J Nagle, Sunita D Nasta, Daniel J Landsburg

Am J Hematol· September 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
NF-κB directs dynamic super enhancer formation in inflammation and atherogenesis.
Jonathan D Brown, Charles Y Lin, Qiong Duan, Gabriel Griffin, Alexander Federation, Steven Bair

Mol Cell· October 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
SQSTM1 is a pathogenic target of 5q copy number gains in kidney cancer.
Lianjie Li, Chuan Shen, Eijiro Nakamura, Kiyohiro Ando, Sabina Signoretti, Steven Bair

Cancer Cell· December 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cardiovascular complications associated with novel angiogenesis inhibitors: emerging evidence and evolving perspectives.
Steven M Bair, Toni K Choueiri, Javid Moslehi

Trends Cardiovasc Med· May 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
No telomere shortening in marrow stroma from patients with MDS.
A Mario Marcondes, Steven Bair, Peter S Rabinovitch, Ted Gooley, H Joachim Deeg

Ann Hematol· July 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Transplantation of allogeneic T cells alters iron homeostasis in NOD/SCID mice.
Steven Bair, Emily Spaulding, Jaakko Parkkinen, Howard M Shulman, Vladimir Lesnikov

Blood· February 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis